Managing relapsed and refractory Hodgkin lymphoma

British Journal of Haematology

Volumn 141, Issue 1, 2008, Pages 3-13

  Brice, Pauline ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Autotransplantation; Chemotherapy; Hodgkin lymphoma; Relapse

Indexed keywords

BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; MONOCLONAL ANTIBODY I 131; NAVELBINE; OXALIPLATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANXIETY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG DOSE INCREASE; DRUG FATALITY; HODGKIN DISEASE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; TOXICITY; TREATMENT RESPONSE; VEIN OCCLUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

EID: 40449086384     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.06998.x     Document Type: Review

References (63)

1. Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, G.B., Zahurak, M.L., Fuller, D., Miller, C.B., Noga, S.J., Fuchs, E., Flinn, I.W., O'Donnell, P., Seifter, E.J., Mann, R.B. Jones, R.J. (2001) Long-term results of blood and bone marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 4314 4321.
2. Aleman, B.M.P., Raemakers, J., Tirelli, U., Bortolus, R., van't Veer, M.B., Lybeert, M.L., Keuning, J.J., Carde, P., Girinsky, T., van der Maazen, R.W., Tomsic, R., Vovk, M., van Hoof, A., Demeestre, G., Lugtenburg, P.J., Thomas, J., Schroyens, W., De Boeck, K., Baars, J.W., Kluin-Nelemans, J.C., Carrie, C., Aoudjane, M., Bron, D., Eghbali, H., Smit, W.G., Meerwaldt, J.H., Hagenbeek, A., Pinna, A. Henry-Amar, M. (2003) Involved field radiotherapy for advanced Hodgkin lymphoma. New England Journal of Medicine, 348, 2396 2406.
3. Alvarez, I., Sureda, A., Caballero, M.D., Urbano-Ispizua, A., Ribera, J.M., Canales, M., Garcia-Conde, J., Sanz, G., Arranz, R., Bernal, M.T., de la Serna, J., Diez, J.L., Moraleda, J.M., Rubio-Felix, D., Xicoy, B., Martinez, C., Mateos, M.V. Sierra, J. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin Lymphoma: results of a Spanish prospective cooperative protocol. Biology of Blood Marrow Transplantation, 12, 172 183.
4. Anderlini, P., Saloba, R., Acholonu, S., Okoroji, G.J., Donato, M., Giralt, S., Andersson, B., Ueno, N.T., Khouri, I., De Lima, M., Hosing, C., Cohen, A., Ippoliti, C., Romaguera, J., Rodriguez, M.A., Pro, B., Fayad, L., Goy, A., Younes, A. Champlin, R.E. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation, 35, 943 951.
5. André, A., Henry-Amar, M., Blaise, D., Colombat, P., Fleury, J., Milpied, N., Cahn, J.Y., Pico, J.L., Bastion, Y., Kuentz, M., Nedellec, G., Attal, M., Ferme, C. Gisselbrecht, C. (1998) Treatment related deaths and second cancer risk after ASCT for Hodgkin's disease. Blood, 92, 1933 1940.
6. André, M., Henry-Amar, M., Pico, J.L., Brice, P., Blaise, D., Kuentz, M., Coiffier, B., Colombat, P., Cahn, J.Y., Attal, M., Fleury, J., Milpied, N., Nedellec, G., Biron, P., Tilly, H., Jouet, J.P. Gisselbrecht, C. (1999) Comparison of high-dose therapy and ASCT with conventional therapy for Hodgkin's disease induction failure: a case-control study. Journal of Clinical Oncology, 17, 222 229.
7. Biermann, P.J., Bagin, R.G., Jagannath, S., Vose, J.M., Spitzer, G., Kessinger, A., Dicke, K.A. Armitage, J.O. (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Annals of Oncology, 4, 767 773.
8. Brice, P., Bastion, Y., Diviné, M., Nedelec, G., Ferrant, A., Gabarre, J., Reman, O., Lepage, E. Ferme, C. (1996) Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer, 78, 1293 1299.
9. Brice, P., Bouabdallah, R., Moreau, P., Diviné, M., André, A., Aoudjane, M., Fleury, J., Anglaret, B., Baruchel, A., Sensebe, L. Colombat, P. (1997) Prognostic factors for survival after high-dose therapy and ASCT for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French Registry. Bone Marrow Transplantation, 20, 21 26.
10. Brice, P., Diviné, M., Simon, D., Coiffier, C., Leblond, V., Simon, M., Voilat, L., Devidas, A., Morschhause, F., Rohrlich, P., Andre, M., Lepage, E. Ferme, C. (1999) Feasibility of tandem ASCT in induction failure or very unfavorable relapse from Hodgkin's disease. Annals of Oncology, 10, 1485 1488.
11. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, M., Cooper, M.R., Henderson, E.S., Green, E.S., Gottlieb, A. Peterson, P.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. The New England Journal of Medicine, 327, 1478 1484.
12. Carella, A.M., Cavaliere, M., Lerma, E., Ferrara, R., Tedeschi, L., Romanelli, A., Vinci, M., Pinotti, G., Lambelet, P., Loni, C., Verdiani, S., De Stefano, F., Valbonesi, M. Corsetti, M.T. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic HSC transplantation as treatment of resistant HD and NHL. Journal of Clinical Oncology, 18, 3918 3924.
13. Castelletti, D., Fracaso, G., Righetti, S., Tridente, G., Scnell, R., Engert, A. Colombatti, M. (2004) A dominant linear B-cell epitope of ricin A-chains the target of neutralizing antibody response in Hodgkin's lymphoma treated with an anti-CD25 immunotoxin. Clinical and Experimental Immunology, 136, 365 372.
14. Chopra, A.K., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G. Goldstone, A.H. (1993) The place of high-dose BEAM therapy and ABMT in poor-risk Hodgkin's disease, a single center eight-year study of 155 patients. Blood, 81, 1137 1145.
15. Connors, J.M., Klimo, P., Adams, G., Burns, B.F., Cooper, I., Meyer, R.M., O'Reilly, S.E., Pater, J., Quirt, I., Sadura, A., Shustik, C., Skillings, J., Sutcliffe, S., Verma, S., Yoshida, S. Zee, B. (1997) Treatment of advanced Hodgkin's disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD, a report from the NCI of Canada clinical trials group. Journal of Clinical Oncology, 15, 1638 1645.
16. Decaudin, D., Levy, R., Lokiec, F., Morshhauser, F., Djeridane, M., Kadouche, J. Pecking, A. (2007) Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody. Anti-Cancer Drugs, 18, 725 731.
17. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386 2395.
18. Evens, A.M., Altman, J.K., Mittal, B.B., Hou, N., Rademaker, A., Patton, D., Kaminer, L., Williams, S., Duffey, S., Variakojis, D., Singhal, S., Tallman, M.S., Mehta, J., Winter, J.M. Gordon, L.I. (2007) Phase I/II trial of total lymphoide irradaition and high-dose chemotherapy with ASCT for relapsed and refractory Hodgkin's lymphoma. Annals of Oncology, 18, 679 688.
19. Ferme, C., Bastion, Y., Lepage, E., Berger, F., Brice, P., Morel, P., Gabarre, J., Nedellec, G., Reman, O., Cheron, N., Oberlin, O. Coiffier, B. (1995) The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Annals of Oncology, 6, 543 549.
20. Fermé, C., Sebban, C., Hennequin, C., Divine, M., Lederlin, P., Gabarre, J., Ferrant, A., Caillot, D., Bordessoule, D., Brice, P., Moulet, I., Berger, F. Lepage, E. (2000) Comparison of chemotherapy to radiotherapy as consolidation of complete response after 6 cycles of chemotherapy for patients with advanced HD: results of the GELA H89 trial. Blood, 95, 2246 2252.
21. Fermé, C., Mounier, N., Diviné, M., Brice, P., Stamatoullas, A., Reman, O., Voillat, L., Jaubert, J., Lederlin, P., Colin, P., Berger, F. Salles, G. (2002) Intensive salvage chemotherapy with high-dose chemotherapy for patients with advanced HD in relapse or failure after initial chemotherapy: results of the GELA H89 trial. Journal of Clinical Oncology, 20, 467 475.
22. Filmont, J.E., Gisselbrecht, C., Cuenca, X., Deville, L., Ertault, M., Brice, P. Gisselbrecht, C. (2007) The impact of pre- and posttransplantation PET using 18-FDG on poor-prognosis lymphoma patients undergoing autologous stem-cell transplantation. Cancer, 110, 1361 1369.
23. Forrest, D.L., Hogge, D.E., Nevill, T.J., Nantel, S.H., Barnett, M.J., Shepherd, J.D., Sutherland, H.J., Toze, C.L., Smith, C.A., Lavoie, J.C., Song, K.W., Voss, N.J., Gascoyne, R.D. Connors, J.M. (2005) HDT and ASCT do not increase the risk of second neoplasms for patient with Hodgkin lymphoma, a comparison of conventional therapy alone versus conventional therapy followed by ASCT. Journal of Clinical Oncology, 23, 7994 8002.
24. Fung, H.C., Stiff, P., Schriber, J., Toor, A., Smith, E., Rodriguez, T., Krishnan, A., Molina, A., Smith, D., Ivers, B., Kogut, N., Popplewell, L., Rodriguez, R., Somio, G., Forman, S.J. Nademanee, A. (2007) Tandem ASCT for patients with primary refractory or poor-risk recurrent Hodgkin lymphoma. Biology of Blood Marrow Transplantation, 13, 594 600.
25. Gajewski, J.L., Philips, G.L., Sobocinski, K.A., Armitage, J.O., Gale, R.P. Champlin, R.E. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. Journal of Clinical Oncology, 14, 572 578.
26. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., d'Amore, F., Biggi, A., Vitolo, U., Selitano, C., Sancetta, R., Trentin, L., Luminari, S., Lanitto, E., Viviani, S., Pierri, I. Levis, A. (2007) Early interim 2 FDG positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma. Journal of Clinical Oncology, 25, 3746 3752.
27. Hall, G.W., Katzilakis, C., Pinkerton, C.R., Nicolin, G., Ashley, S., Mccarthy, K., Daw, S., Hewitt, M., Wallace, W.H. Shankar, A. (2007) Outcome of children with NLPHL, a children's cancer and leukemia group report. British Journal of Haematology, 138, 761 768.
28. Hasenclever, D. Diehl, V. (1998) A prognostic score for advanced hodgkin's disease. New England Journal of Medicine, 339, 1506 1514.
29. Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V. Engert, A. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood, 96, 1280 1286.
30. Josting, A., Franklin, J., Sieber, M., Diehl, V. Engert, A. (2002) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 20, 220 231.
31. Josting, A., Nogova, L., Franklin, J., Glossmann, J.P., Eich, H.T., Sieber, M., Scober, T., Boettcher, H.D., Schulz, U., Muller, R.P., Diehl, V. Engert, A. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 23, 1522 1529.
32. Khouri, I.F., Keating, M., Korbling, M., Przepiorka, G., Anderlini, A. O'Brien, S. (1998) Transplant-lite : induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology, 16, 2817 2824.
33. Lavoie, J.C., Connors, J.M., Philips, G.L., Reece, D., Barnett, M.J., Forrest, D.L., Gascoyne, R., Hogge, D.E., Nantel, S.H., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L., Voss, N.J. Nevill, T.J. (2005) HDT and ASCT for relapsed and refractory Hodgkin lymphoma, long-term outcome of the first 100 patients transplanted in Vancouver. Blood, 106, 1473 1479.
34. Leonard, J.P., Rosenblatt, J.D., Bartlett, N., Gopal, A., Younes, A., Fisher, D., Foss, F., Forero, A. McDonald, M. (2004) Phase II study of SGN-30 (anti-CD30 monoclonal antibody in patients with refractory or recurrent Hodgkin's disease. Blood (ASH Annual Meeting Abstracts), 104, 2635.
35. Lieskovsky, Y.E., Donaldson, S.S., Torres, M.A., Wong, R.M., Amylon, M.D., Link, M.P. Agarwal, R. (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. Journal of Clinical Oncology, 22, 4532 4540.
36. Lin, T.S., Avalos, B.R., Penza, S.L., Marcucci, G., Elder, P.J. Copelan, E.A. (2002) Second autologous stem cell transplantation for multiply relapsed Hodgkin's disease. Bone Marrow Transplantation, 29, 763 767.
37. Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D. Hudson, G.V. (1993) Dose intensification with ABMT in relapsed and resistant Hodgkin's disease, results of a BNLI randomised trial. Lancet, 341, 1051 1054.
38. Lohri, A., Barnett, M., Fairey, R.N., O'Reilly, S.E., Phillips, G.L., Reece, D., Voss, N. Connors, J.M. (1991) Outcome of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1980. Blood, 77, 2292 2298.
39. Majhail, N.S., Weisdorf, D.J., Defor, T.E., Miller, J.S., McGlave, P.B., Slungaard, A., Arora, M., Ramsay, N.K., Orchard, P.J., MacMillan, M.L. Burns, L.J. (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma. Biology of Blood Marrow Transplantation, 12, 1065 1072.
40. Milpied, N., Fielding, A.K., Pearce, R.M., Ernst, P. Goldstone, A.H. (1996) Allogeneic bone-marrow transplant is not better than autologous for patients with relapsed HD from the EBMT. Journal of Clinical Oncology, 14, 1291 1296.
41. Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walitits, J., Coady-lyons, N., Qin, J., Franck, R., Bertino, J.R., Goy, A., Noy, A., O'Brien, J.P., Strauss, D., Portlock, C. Yahalom, J. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 97, 616 623.
42. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzales, M., Zelenetz, A.D. Yahalom, J. (2004) Effectiveness of high-dose chemoradiotherapy and ASCT for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal Haematology, 124, 645 652.
43. Nogova, L., Rudiger, T. Engert, A. (2006) Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology. American Society of Hematology. Education Program, 266 272.
44. Peggs, K.S., Hunter, A., Chopra, R., Parkera Mahendra, P., Milligan, D., Craddock, C., Pettengel, R., Dogan, A., Thomson, K.J., Morris, E.C., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D. Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin lymphoma effect after RIC allogeneic transplantation. Lancet, 365, 1934 1941.
45. Popat, U., Hosing, C., Saliba, R.M., Anderlini, P., Van Besien, K., Przepiorka, G., Khouri, I.F., Gajewski, J., Claxton, D., Giralt, S., Rodriguez, M., Romaguera, J., Hagemeister, F., Ha, C., Cox, J., Cabanillas, F., Andersson, B.S. Champlin, R.E. (2004) Prognostic factors for disease progression after HDT and ASCT for recurrent or refractory Hodgkin lymphoma. Bone Marrow Transplantation, 33, 1015 1023.
46. Reece, D.E., Connors, J.M., Spinelli, J.J., Barnett, N., Fairey, R.N., Klingemann, H.G., Nantel, S.H., O'Reilly, S., Sheperd, J.D. Sutherland, H.J. (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide cisplatine and ABMT for Hodgkin's disease in first relapse after combination chemotherapy. Blood, 83, 1193 1199.
47. + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 101, 420 424.
48. Rodriguez, J., Rodriguez, M.A., Fayad, L., McLaughlin, P., Swan, F., Sarris, A., Romaguera, J., Andersson, B., Cabanillas, F. Hagemeister, F.B. (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood, 93, 3632 3636.
49. Santoro, A., Bredenfeld, L., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., Fielder, F., soto Parra, H., Benoehr, C., Pacini, M., Bonadonna, G. Diehl, V. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease : results of a multicenter phase II study. Journal of Clinical Oncology, 18, 2615 2619.
50. Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michielli, N., Nozza, A., Sarina, B., Morenghi, E., Castagna, L., Tirelli, U. Balzarotti, M. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92, 35 41.
51. Schellong, G., Dörffel, W., Claviez, A., Körholz, D., Mann, G. Scheel-Walter, H.G. (2005) Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the Pediatric DAL/GPOH-HD Study Group. Journal of Clinical Oncology, 23, 6181 6189.
52. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with ASCT for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 325, 2065 2071.
53. Schmitz, N., Haverkampf, H., Josting, A., Diehl, V., Pfistner, B., Bokemeyer, A. Goldstone, A.H. (2005). Long term follow up in relapsed Hodgkin's disease: comparing conventional chemotherapy to high-dose chemotherapy with ASCT. Journal of Clinical Oncology, 23, 16S. ASCO Annual Meeting Proceedings (Abstract 6508).
54. Schnell, R., Dietlein, M., Staak, J.O., Borchman, P., Schomaeker, K., Fisher, T., Eschner, W., Hansen, H., Morschhauser, F., Schicha, H., Diehl, V., Raubitschek, A. Engert, A. (2005) Treatment of refractory Hodgkin lymphoma patients with an Iodine-131 labeled murine anti-CD30 monoclonal antibody. Journal of Clinical Oncology, 23, 4669 4678.
55. Schot, B.W., Zijlstra, J.M., Sluiter, W.J., van Imhoff, G.W., Pruim, J., Vaalburg, W. Velenga, E. (2007) Early FDG-PET assessment in combination with clinical scores determines prognosis in recurring lymphoma. Blood, 109, 486 491.
56. Sieniawski, M., Franklin, J., Nogova, L., Glossmann, J.P., Schober, T., Nisters-Backes, H., Diehl, V. Josting, A. (2007) Outcome of patients experiencing progression or relapse after primary treatment with 2 cycles of chemotherapy and radiotherapy for early-stage favourable Hodgkin lymphoma. Journal of Clinical Oncology, 25, 2000 2005.
57. Sureda, A., Arranz, R., Iriondo, E., Carreras, E., Lahuerta, J.J., Garcia-Conde, J., Jarque, I., Caballero, M.D., Ferra, C., Lopez, A., Garcia-larana, J., Cabrera, R., Carrera, D., Leon, A., Rifon, J., Mataix, R., Morey, M., Moraleda, J.M., Altes, A., Lopes-Guillermo, A., de la Serna, J., Sierra, J. Conde, E. (2001) ASCT for Hodgkin's disease: results and prognostic factors in 494 patients from the spanish cooperative group. Journal of Clinical Oncology, 19, 1395 1404.
58. Sweetenham, J.W., Taghipour, G., Milligan, D., Blystad, A.K., Cabalerro, D. Fassas, A. (1997) HDT and ASCT for patients with Hodgkin's disease in first relapse after chemotherapy, a report of the EBMT. Bone Marrow Transplantation, 20, 745 752.
59. Sweetenham, J.W., Carella, A.M., Taghipour, G., Cunningham, D., Marcus, R., Della Volpe, A., Linch, D.C., Schmitz, N. Goldstone, A.H. (1999) High-dose therapy and autologous stem-cell transplantation for patients with Hodgkin's disease who do not enter into complete remission after induction chemotherapy: results of 175 patients reported to the EBMT. Journal of Clinical Oncology, 17, 3101 3109.
60. Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di Nicola, M., Cortelazzo, S., Rosato, R., Rosanelli, C., Di renzo, N., Musso, M., Pavone, E., Santini, G., Pescarollo, A., De Crescenzo, A., Federico, M., Gallamini, A., Pregno, P., Romano, R., Coser, P., Gallo, E., Boccadoro, M., Barbui, T., Pileri, A., Gianni, A.M. Levis, A. (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer, 97, 2748 2759.
61. Vriesendorp, H.M. Quadric, S.M. (2000) Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease. Cancer Biother Radiopharm, 15, 432 445.
62. Yahalom, J., Gulati, S.C., Toia, M., Maslak, P., McCarron, E.G., O'Brien, J.P., Portlock, C.S., Strauss, D.J., Phillips, J. Fuks, Z. (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. Journal of Clinical Oncology, 11, 1062 1070.
63. Younes, A., Pro, B. Fayad, L. (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 107, 1731 1732.